Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Vanguard Short Term Corporate Bond ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.8 (market cap $6.04B), while Vanguard Short Term Corporate Bond ETF trades at $77.29 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 8.6× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| IOVA | VCSH | |
|---|---|---|
Market Cap | $6.04B | $51.90B |
Volume | 14,805,993 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $14.82 | $80.20 |
52-Week Low | $1.81 | $77.03 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCSH trades at $77.285 with minimal daily movement (+0.02%). The technical outlook is bearish with moving averages signaling caution, though oscillators remain neutral. Recent news highlights VCSH's competitive 4.5% dividend yield and low 0.03% expense ratio, positioning it as a stable income alternative to CDs or stable value funds. The fund's short 2.7-year duration minimizes interest rate risk, but credit spreads remain tight, limiting near-term upside potential.
VCSH offers conservative investors higher yields than traditional safe-harbor investments with minimal volatility. The primary risk involves corporate credit exposure during economic downturns, while the main opportunity lies in its attractive risk-adjusted returns for short-term bond allocations. Current market sentiment is neutral with some institutional rotation observed in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
